Telix Pharmaceuticals Limited cash flow statement TLX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Telix Pharmaceuticals Limited used $17.3 million of cash from operations. It spent $25.7 million on capital expenditures. Free cash flow was negative, at -$43.0 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
Operating
Depreciation and amortization
22
Stock-based compensation
19
Operating cash flow
-17
Investing
Capital expenditures
26
Investing cash flow
-286
Financing
Debt issued
1
Debt repaid
1
Financing cash flow
-4
Change in cash
Effect of exchange rate
9
Free cash flow
-43
Per share
Free cash flow per share
-0.13
Ratios
Free cash flow margin
-5.35%
Capital expenditures to revenue
3.20%
Stock-based compensation to revenue
2.38%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TLX (Nasdaq), TLPPF (OTC)
Fiscal year ends
December 31
Incorporated in
Australia
Headquarters
North Melbourne, Australia
SEC filer status
Large accelerated filer
SEC CIK
2007191

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.